|Bid||4.9000 x 3000|
|Ask||4.9700 x 800|
|Day's range||4.4100 - 5.0700|
|52-week range||4.3430 - 15.8640|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||15 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.25|
BOULDER, Colo., January 10, 2022--Inscripta said Ginkgo Bioworks has adopted the Onyx genome engineering platform as part of its commitment to cutting-edge tech in its foundries.
NEW YORK, December 17, 2021--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. ("Ginkgo" or the "Company") (NYSE: DNA) (NASDAQ: SRNG) securities from May 11, 2021 through October 5, 2021, inclusive (the "Class Period"). Investors have until January 18, 2022 to apply to the Court to be
NEW YORK, December 03, 2021--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. (NYSE: DNA) (NASDAQ: SRNG) between May 11, 2021 and October 5, 2021, both dates inclusive (the "Class Period"), of the important January 18, 2022 lead plaintiff deadline.